Cargando…
Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
BACKGROUND: Programmed cell death ligand‐1 (PD‐L1) is a useful biomarker in non‐small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD‐L1 expression. In thi...
Autores principales: | Chen, Minjiang, Xu, Yan, Zhao, Jing, Li, Ji, Liu, Xiangning, Zhong, Wei, Wang, Mengzhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410567/ https://www.ncbi.nlm.nih.gov/pubmed/34291566 http://dx.doi.org/10.1111/1759-7714.14075 |
Ejemplares similares
-
Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023) -
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
por: Munari, Enrico, et al.
Publicado: (2017) -
Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
por: Munari, Enrico, et al.
Publicado: (2018) -
Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023) -
The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis
por: Wang, Yang, et al.
Publicado: (2021)